Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Gynae 2023 | RAD51 foci in cancer-associated circulating cells associates with treatment outcomes in HGSOC

High-grade serous ovarian cancer (HGSOC) is one of the most common types of ovarian cancer, and homologous recombination deficiency (HRD) is a biomarker of response to platinum-based chemotherapy and PARP inhibition. In this interview, Marcia Hall, MBBS, PhD, FRCP, Mount Vernon Cancer Centre, Northwood, UK, shares a novel identification of biomarkers of response to therapy using circulating tumor cells. RAD51 foci in cancer-associated circulating cells are associated with treatment outcomes in patients with high-grade serous ovarian cancer, with increased RAD51 foci at baseline associating with poorer progression-free survival. This interview took place at the ESMO Gynaecological Cancers Congress 2023 in Barcelona, Spain

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.